Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2019-02-14 Major Shareholding Noti…
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2019-02-14 English
FORM 6-K
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Bioblast Pharma Ltd., with the SEC. It includes a Notice of Meeting, Proxy Statement, and Proxy Card for an Extraordinary General Meeting of Shareholders. The document is relatively short (2740 characters) and primarily serves to announce and provide materials related to a shareholder meeting. It does not contain financial statements or detailed financial analysis. The presence of a Proxy Statement and Notice of Meeting indicates it is related to shareholder voting information. According to the filing definitions, materials sent to shareholders to provide information and request votes for meetings are classified as Proxy Solicitation & Information Statement (PSI). Therefore, the appropriate classification is PSI with high confidence.
2019-01-31 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Bioblast Pharma Ltd., with the SEC. It includes unaudited financial information for the six months ended June 30, 2018, which corresponds to an interim period. The document explicitly states it contains financial information for a half-year period and is submitted to meet Nasdaq requirements for interim financial reporting. The length of the document is 2394 characters, which is relatively short but contains substantive financial data (unaudited financial information for six months). Therefore, it is a comprehensive interim/quarterly report rather than just an announcement or certification. According to the definitions, this fits best under Interim / Quarterly Report (IR).
2018-12-31 English
FORM 6-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, Bioblast Pharma Ltd., with the SEC. It reports the results of the Annual and Extraordinary General Meeting of Shareholders held on December 27, 2018. The document specifically states it contains the results of the shareholder meeting and references agenda items approved at the meeting. The content is focused on the voting results from the shareholders' meeting rather than the meeting materials or presentations. The document length is short (2402 characters), and it is not a full report but a formal announcement of voting results. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2018-12-27 English
6-K
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Bioblast Pharma Ltd., with the SEC. It primarily announces an amendment to the notice of an Annual and Extraordinary General Meeting of Shareholders, including rescheduling the meeting date and attaching the Proxy Statement and Proxy Card for the meeting. The document does not contain financial statements or detailed financial data but rather provides meeting-related materials and notices. The presence of Proxy Statement and Proxy Card attachments indicates this is related to shareholder meeting materials. Given the document length is 3308 characters (under 5000), and it mainly announces meeting materials and changes, it fits best as a Proxy Solicitation & Information Statement (PSI) filing rather than the meeting itself or a full annual report. Therefore, the classification is PSI with high confidence.
2018-12-06 English
6-K
AGM Information Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Bioblast Pharma Ltd., with the SEC. It contains a Notice of Meeting for the Annual and Extraordinary General Meeting of Shareholders scheduled for December 26, 2018. The document is relatively short (2523 characters) and primarily serves to announce the meeting and provide the notice, rather than presenting detailed financial data or full reports. It does not contain financial statements or detailed management discussion. The content aligns with materials shared for an Annual General Meeting, specifically the Notice of Meeting. Therefore, the document fits the category of AGM Information (AGM-R).
2018-11-21 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.